At a glance
ClinicalIndex Comparison RecordStandardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
An Open-labeled Study to Evaluate Efficacy of Combining Erbitux Plus Concurrent Chemo-radiotherapy in Locally Advanced Esophageal Squamous Cell Carcinoma (ESCC)
In Brief
A Phase 2 clinical trial evaluating cetuximab (Erbitux), Paclitaxel, and 2 other interventions for Esophageal Cancer. Completed, enrolled 55 participants across 1 site.
Detailed Summary
The purpose of this study is to determine whether the treatment of locally advanced esophageal squamous cell carcinoma (ESCC)with cetuximab in combination with paclitaxel, cisplatin and radiation improve clinical outcomes.
Study Details
Timeline
Interventions
Cetuximab,injection,loading dose400 mg/m\^2,(Day1 in Week1) followed by 250 mg/m\^2(Day1, every week for Weeks 2-8)
Paclitaxel,injection,loading dose 45 mg/m\^2,(Day1 in every week for Weeks 2-8)
Cisplatin,injection,loading dose 20 mg/m\^2,(Day1 in every week for Weeks 2-8)
Radiation, External beam therapy, total 59.4 Gy , 33 fractions, 1.8 Gy per fraction.(Day 1-Day 5 in every week 2-week 8).